X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/johnson--johnson-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-tremfya-guselkumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-302085776.html
https://www.prnewswire.com/news-releases/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study-302040661.html
https://www.prnewswire.com/news-releases/new-real-world-data-show-tremfya-guselkumab-was-associated-with-clinically-meaningful-improvements-in-patient-reported-outcomes-for-adults-living-with-active-psoriatic-arthritis-301980227.html
https://endpts.com/jjs-first-psoriasis-study-exclusive-to-patients-of-color-opens-door-to-new-marketing-communications/
https://www.prnewswire.com/news-releases/new-phase-3-tremfya-guselkumab-results-in-ulcerative-colitis-show-a-77-percent-overall-clinical-response-rate-and-early-symptom-improvement-301963553.html
https://www.prnewswire.com/news-releases/janssen-announces-tremfya-guselkumab-demonstrates-significant-skin-clearance-in-first-of-its-kind-prospective-large-scale-study-dedicated-to-people-of-color-living-with-moderate-to-severe-plaque-psoriasis-301963282.html
https://www.prnewswire.com/news-releases/tremfya-guselkumab-maintains-key-efficacy-endpoints-through-three-years-for-adults-with-moderately-to-severely-active-crohns-disease-in-a-phase-2-study-301956858.html
https://www.prnewswire.com/news-releases/janssen-highlights-latest-research-for-tremfya-guselkumab-and-investigational-targeted-oral-peptide-jnj-2113-in-moderate-to-severe-plaque-psoriasis-at-the-european-academy-of-dermatology-and-venereology-eadv-congress-301949936.html
https://www.indianpharmapost.com/news/janssen-tremfya-excels-as-psoriasis-treatment-outshining-il-17s-says-globaldata-14200
https://www.clinicaltrialsarena.com/news/janssen-tremyfa-ulcerative-colitis/
https://www.prnewswire.com/news-releases/first-phase-3-tremfya-guselkumab-data-in-inflammatory-bowel-disease-show-positive-induction-results-among-patients-with-moderately-to-severely-active-ulcerative-colitis-301818808.html
https://johnsonandjohnson.gcs-web.com/static-files/e4b41e8c-23c2-4039-b37b-73312f1549a1
https://www.prnewswire.com/news-releases/tremfya-guselkumab-real-world-data-analyses-show-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-patients-living-with-moderate-to-severe-plaque-psoriasis-301774516.html
https://www.prnewswire.com/news-releases/tremfya-guselkumab-demonstrates-a-differentiated-binding-mechanism-from-risankizumab-in-in-vitro-studies-301761742.html
https://www.prnewswire.com/news-releases/new-tremfya-guselkumab-post-hoc-analysis-reveals-active-psoriatic-arthritis-patients-with-early-efficacy-had-meaningful-long-term-improvement-in-health-related-quality-of-life-301673947.html
https://endpts.com/jj-uncorks-new-tremfya-data-in-ulcerative-colitis-as-its-rival-awaits-an-fda-decision/
https://www.prnewswire.com/news-releases/new-tremfya-guselkumab-data-show-an-overall-clinical-response-rate-of-approximately-80-percent-in-a-phase-2b-induction-study-of-adults-with-moderately-to-severely-active-ulcerative-colitis-301656396.html
https://pharmanewsintel.com/news/jj-ulcerative-colitis-clinical-trial-produces-high-rate-of-remission
https://endpts.com/jjs-janssen-unveils-phii-ulcerative-colitis-data-for-tremfya-combo-looking-to-expand-the-drugs-footprint/
https://www.prnewswire.com/news-releases/results-of-novel-clinical-study-of-guselkumab-and-golimumab-combination-therapy-show-adults-with-moderately-to-severely-active-ulcerative-colitis-maintained-higher-rates-of-clinical-histologic-and-endoscopic-remission-at-week-38-301644127.html
http://www.koreabiomed.com/news/articleView.html?idxno=13940
https://www.prnewswire.com/news-releases/new-data-show-patients-treated-with-first-in-class-tremfya-guselkumab-achieve-durable-efficacy-across-joint-and-axial-symptoms-of-active-psoriatic-arthritis-through-two-years-301558618.html
https://www.prnewswire.com/news-releases/janssen-presents-study-results-showing-clinical-efficacy-for-tremfya-guselkumab-and-long-term-safety-profile-for-stelara-ustekinumab-for-patients-living-with-inflammatory-bowel-disease-at-digestive-disease-week-2022-301554314.html
https://www.prnewswire.com/news-releases/new-data-show-majority-of-adults-with-moderate-to-severe-plaque-psoriasis-treated-with-first-in-class-tremfya-guselkumab-experienced-durable-skin-clearance-through-five-years-regardless-of-metabolic-syndrome-status-baseline-di-301510573.html
https://www.prnewswire.com/news-releases/results-of-novel-clinical-study-show-adults-with-moderately-to-severely-active-ulcerative-colitis-achieved-higher-rates-of-clinical-response-clinical-remission-and-endoscopic-improvement-at-12-weeks-with-guselkumab-and-golimumab-301486054.html
https://www.fiercepharma.com/pharma/j-j-lands-tremfya-one-two-punch-ibd-first-ulcerative-colitis-data-and-long-term-crohn-s
https://www.europeanpharmaceuticalreview.com/news/167968/tremfya-psoriatic-arthritis-patients-nma/
http://www.pharmafile.com/news/596111/crohn-s-patients-see-65-remission-clinical-trial
https://www.europeanpharmaceuticalreview.com/news/165592/crohns-patients-achieve-65-percent-clinical-remission-with-tremfya/
https://www.prnewswire.com/news-releases/new-phase-3-first-in-class-tremfya-guselkumab-data-show-durability-of-joint-efficacy-including-low-rates-of-structural-damage-progression-and-a-demonstrated-safety-profile-in-adults-with-active-psoriatic-arthritis-psa-301412935.html
https://endpts.com/j-roche-regeneron-drugs-among-latest-to-earn-eu-advisory-groups-nod/
https://www.fiercepharma.com/pharma/challenging-abbvie-and-lilly-psoriatic-arthritis-j-j-touts-two-year-data-for-tremfya
https://www.prnewswire.com/news-releases/new-phase-3-data-show-first-in-class-tremfya-guselkumab-achieved-complete-skin-clearance-and-favorable-joint-efficacy-in-adult-patients-with-active-psoriatic-arthritis-psa-through-two-years-301248005.html
https://leo-pharma.com/media-center/news/leo-pharma-initiates-head-to-head-study-to-evaluate-brodalumab-versus-guselkumab
https://www.businesswire.com/news/home/20201124006087/en/European-Commission-Approves-Janssen%E2%80%99s-TREMFYA%C2%AE%E2%96%BC-guselkumab-a-First-in-Class-Treatment-for-Active-Psoriatic-Arthritis-PsA
https://www.prnewswire.com/news-releases/new-first-in-class-phase-3-data-demonstrate-tremfya-guselkumab-maintained-skin-clearance-rates-through-nearly-5-years-of-continuous-use-in-adult-patients-with-moderate-to-severe-plaque-psoriasis-301152949.html
https://www.biospace.com/article/releases/tremfya-guselkumab-induces-clinical-and-endoscopic-improvements-in-patients-with-moderately-to-severely-active-crohn-s-disease-based-on-interim-results-from-phase-2-study/
https://www.newswire.ca/news-releases/health-canada-approves-tremfya-r-guselkumab-injection-a-first-in-class-selective-interleukin-il-23-inhibitor-for-active-psoriatic-arthritis-822702384.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061
https://endpts.com/j-merck-kgaa-spinout-ups-series-a-tally-to-e20-1m/
https://www.fiercepharma.com/pharma/j-j-earns-fda-nod-for-next-gen-immunology-med-tremfya-psoriatic-arthritis
http://www.pharmafile.com/news/551244/tremfyas-skin-clearance-benefit-lasts-four-years-plaque-psoriasis-patients-janssen-says
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061
https://www.prnewswire.com/news-releases/new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-301070016.html
https://www.businesswire.com/news/home/20200406005432/en/Lancet-Simultaneously-Publishes-Phase-3-Studies-Detailing/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://in.reuters.com/article/us-johnson-johnson-china-tremfya/china-regulator-approves-imports-of-jjs-tremfya-idINKBN1YV0HT
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061
Market Place
Share 
